Ipsen Initiates a Share Buy-Back Program to Cover Its Employee Free Share-Allocation Plan
Ipsen has appointed an investment-services provider to acquire 125,000 shares, representing approximately 0.15% of its share capital, over a three-month period. This purchase is aligned with the employee free share-allocation plan and was authorized by the Combined Shareholders’ meeting on May 24, 2022.
In FY 2021, Ipsen recorded Specialty Care sales of €2.6 billion, operating in over 100 countries. The company is recognized for its focus on Oncology, Rare Disease, and Neuroscience.
- Acquisition of 125,000 shares could enhance employee engagement through share-allocation.
- Demonstrates confidence in long-term growth strategy with employee incentives.
- None.
Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase 125,000
This program is made pursuant to the authorization granted by the Combined Shareholders’ meeting, held on
About Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of
Forward-looking statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s 2021 Universal Registration Document, available on www.ipsen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531006010/en/
Investors
Vice President, Investor Relations
+44 7584 349 193
Investor Relations Manager
+33 6 64 26 17 49
Media
Executive Vice President, Communications and Public Affairs
+44 7876 391 429
Senior Manager, Global Media Relations
+33 6 69 09 12 96
Source:
FAQ
What is the recent share acquisition by Ipsen (IPSEY)?
When was the share acquisition authorized for Ipsen (IPSEY)?
What were Ipsen's Specialty Care sales in FY 2021?
In how many countries does Ipsen (IPSEY) operate?
